Kedokteran & Kesehatan editorial
Open AccessOA2023
Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial
MONITOR-HF randomised 348 patients with NYHA class III chronic heart failure to CardioMEMS haemodynamic monitoring or standard care. At 12 months, the KCCQ overall summary score improved by 7.13 points more in the monitoring group, with a 55% reduction in the odds of clinically significant deterioration.
J. Brugts; S. Radhoe; P. Clephas; Dilan Aydin; M. V. van Gent; M. Szymanski; M. Rienstra; M. van den Heuvel; C. D. da Fonseca; G. Linssen; C. J. W. Borleffs; E. Boersma; F. Asselbergs; A. Mosterd; H. Brunner-la Rocca; R. D. de Boer; M. Emans; S. Beeres; L. Heerebeek; C. Kirchhof; J. van Ramshorst; R. Spee; T. Smilde; M. van Eck; E. Kaplan; R. Hazeleger; R. Tukkie; M. Feenema; W. Kok; V. V. van Halm; M. Handoko; R. van Kimmenade; M. Post; N. van Mieghem; O. Manintveldยท The Lancetยท 2023ยท DOI 10.1016/s0140-6736(23)00923-6
The core problem
Heart failure is a major cause of morbidity and mortality worldwide, and hospitalisations for decompensation impose a substantial burden on patients and health-care systems. Remote monitoring of pulmonary artery pressure using the CardioMEMS-HF system (Abbott Laboratories) has been studied predominantly in the USA, but randomised evidence from European health-care systems and from patients treated with contemporary guideline-directed medical therapy (GDMT) is limited. The MONITOR-HF trial was designed to address this gap by evaluating the effect of haemodynamic monitoring on quality of life and heart failure hospitalisations in a Dutch population with chronic heart failure, irrespective of ejection fraction. The trial was conducted in 25 centres in the Netherlands and was prospectively registered (NTR7673; NL7430).
Innovation
MONITOR-HF was an open-label, randomised, controlled trial. Eligible patients had chronic heart failure of New York Heart Association (NYHA) class III and a previous heart failure hospitalisation, irrespective of left ventricular ejection fraction. Patients were randomly assigned (1:1) to haemodynamic monitoring with the CardioMEMS-HF system or to standard care. All patients were scheduled for clinical visits at 3 and 6 months, and every 6 months thereafter, up to 48 months. The primary endpoint was the mean difference in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score at 12 months. Secondary endpoints included heart failure hospitalisations and a responder analysis of KCCQ changes. All analyses were by intention-to-treat. The trial was funded by the Dutch Ministry of Health, Health Care Institute (Zorginstituut), and Abbott Laboratories.
Introduction
Heart failure is a major cause of morbidity and mortality worldwide, and hospitalisations for decompensation impose a substantial burden on patients and health-care systems. Remote monitoring of pulmonary artery pressure using the CardioMEMS-HF system (Abbott Laboratories) has been studied predominantly in the USA, but randomised evidence from European health-care systems and from patients treated with contemporary guideline-directed medical therapy (GDMT) is limited. The MONITOR-HF trial was designed to address this gap by evaluating the effect of haemodynamic monitoring on quality of life and heart failure hospitalisations in a Dutch population with chronic heart failure, irrespective of ejection fraction. The trial was conducted in 25 centres in the Netherlands and was prospectively registered (NTR7673; NL7430).
Why it matters
In this randomised trial, haemodynamic monitoring of pulmonary artery pressure with the CardioMEMS-HF system significantly improved quality of life and reduced heart failure hospitalisations in patients with moderate-to-severe chronic heart failure treated according to contemporary guidelines. The 7.13-point improvement in KCCQ overall summary score exceeds the commonly accepted minimal clinically important difference of 5 points, and the responder analysis confirmed both a higher likelihood of improvement and a lower likelihood of deterioration. The safety profile was favourable, with high freedom from device-related complications and sensor failure. These findings add to the aggregate evidence for remote pulmonary artery pressure monitoring and may inform guideline recommendations and implementation in European health-care systems. The open-label design and the relatively short 12-month primary endpoint are potential limitations, but the results are consistent with previous US trials and extend them to a GDMT-treated population. The trial was funded by the Dutch Ministry of Health, Health Care Institute (Zorginstituut), and Abbott Laboratories.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ